<DOC>
	<DOC>NCT00882258</DOC>
	<brief_summary>Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.</brief_summary>
	<brief_title>Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase. At the three-month treatment visit, subjects will be entered into an open-label extension treatment protocol, if deemed eligible. At four months after their first treatment visit, subjects not electing to enter the open-label study will be assessed at a final follow-up visit.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>At least one leiomyoma must have been identifiable and measurable by abdominal/pelvic ultrasound. Must have had a history of one or both of the following leiomyomataassociated symptoms, excessive menstrual bleeding, or pain Postmenopausal women, as defined as one or more of the following: 1. six months or more (immediately prior to Screening visit) without a menstrual period, or 2. prior hysterectomy and/or oophorectomy Subjects with documented endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Uterine fibroids</keyword>
</DOC>